Goldman Sachs raised its target price for Novo Nordisk and Novo Nordisk, optimistic about the potential of semaglutide oral formulations.

Goldman Sachs raised the target stock price of Danish pharmaceutical company Novo Nordisk, citing the company's recent launch of the oral semaglutide formulation, which is expected to boost market sentiment in the short term. Analyst James Quigley pointed out that the market focus in the first half of 2026 will be on Novo Nordisk's oral semaglutide formulation and the progress of the rival oral drug Ozempic by Eli Lilly. Goldman Sachs stated that the oral semaglutide formulation should bring positive earnings growth momentum to Novo Nordisk in the short term. The target price was raised from 352 Danish kroner per share to 436 Danish kroner; the stock closed at 373.85 Danish kroner on Wednesday.